Guanghui Han

Guanghui Han

Auto-generated profile, based on publicly available information

Guanghui Han

Microchemistry, Proteomics & Lipidomics, Genentech Inc., South San Francisco, CA, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 August 2020 in Nature
Verified
Journal Article
Closed access
PDF file
TCThomas Clairfeuille
Thomas Clairfeuille
KBKerry R. Buchholz
Kerry R. Buchholz
QLQingling Li
Qingling Li
EVErik Verschueren
Erik Verschueren
PLPeter Liu
Peter Liu
SRSteven Rutherford
Steven Rutherford

19 October 2018 in mAbs
Verified
Journal Article
Open access
ABAaron O. Bailey
Aaron O. Bailey
GHGuanghui Han
Guanghui Han
WPWilson Phung
Wilson Phung
PGPaul Gazis
Paul Gazis
JSJennifer Sutton
Jennifer Sutton
WSWendy Sandoval
Wendy Sandoval
The preponderance and diversity of charge variants in therapeutic monoclonal antibodies has implications for antibody efficacy and degradation. Understanding the extent and impact of minor antibody variants is of great interest, and it is also a critical regulatory requirement. Traditionally, a combination of approaches is used to characterize antibody charge heterogeneity, including ion exchange chromatography and independent mass spectrometric variant site mapping after proteolytic digestion. Here, we describe charge variant native mass spectrometry (CVMS), an integrated native ion exchange mass spectrometry-based charge variant analytical approach that delivers detailed molecular information in a single, semi-automated analysis. We utilized pure volatile salt mobile phases over a pH gradient that effectively separated variants based on minimal differences in isoelectric point. Characterization of variants such as deamidation, which are traditionally unattainable by intact mass due to their minimal molecular weight differences, were measured unambiguously by mass and retention time to allow confident MS1 identification. We demonstrate that efficient chromatographic separation allows introduction of the purified forms of the charge variant isoforms into the Orbitrap mass spectrometer. Our CVMS method allows confident assignment of intact monoclonal antibody isoforms of similar mass and relative abundance measurements across three orders of magnitude dynamic range.

27 November 2018 in Analytical Chemistry
Verified
Journal Article
Closed access
CRChengfeng Ren
Chengfeng Ren
ABAaron Oakley Bailey
Aaron Oakley Bailey
EVErica C VanderPorten
Erica C VanderPorten
AOAngela Oh
Angela Oh
WPWilson Phung
Wilson Phung
WSWendy Sandoval
Wendy Sandoval

26 July 2019 in mAbs
Verified
Journal Article
Open access
KJKamal Kishore Joshi
Kamal Kishore Joshi
WPWilson Phung
Wilson Phung
GHGuanghui Han
Guanghui Han
YYYiyuan Yin
Yiyuan Yin
IKIngrid Kim
Ingrid Kim
PCPaul J. Carter
Paul J. Carter
Multiple strategies have been developed to facilitate the efficient production of bispecific IgG (BsIgG) in single host cells. For example, we previously demonstrated near quantitative (≥90%) formation of BsIgG of different species and isotypes by combining ‘knob-into-hole’ mutations for heavy chain heterodimerization with engineered antigen-binding fragments (Fabs) for preferential cognate heavy/light chain pairing. Surprisingly, in this study we found high yield (>65%) of BsIgG1 without Fab engineering to be a common occurrence, i.e., observed for 33 of the 99 different antibody pairs evaluated. Installing charge mutations at both CH1/CL interfaces was sufficient for near quantitative yield (>90%) of BsIgG1 for most (9 of 11) antibody pairs tested with this inherent cognate chain pairing preference. Mechanistically, we demonstrate that a strong cognate pairing preference in one Fab arm can be sufficient for high BsIgG1 yield. These observed chain pairing preferences are apparently driven by variable domain sequences and can result from a few specific residues in the complementarity-determining region (CDR) L3 and H3. Transfer of these CDR residues into other antibodies increased BsIgG1 yield in most cases. Mutational analysis revealed that the disulfide bond between heavy and light chains did not affect the yield of BsIgG1. This study provides some mechanistic understanding of factors contributing to antibody heavy/light chain pairing preference and subsequently contributes to the efficient production of BsIgG in single host cells.

28 June 2019 in PLOS ONE
Verified
Journal Article
Open access
PDF file
WSWhitney Shatz-Binder
Whitney Shatz-Binder
PHPhilip E Hass
Philip E Hass
NPNikhil Peer
Nikhil Peer
MPMaciej T Paluch
Maciej T Paluch
CBCraig Blanchette
Craig Blanchette
RKRobert F Kelley
Robert F Kelley
Innovative protein engineering and chemical conjugation technologies have yielded an impressive number of drug candidates in clinical development including >80 antibody drug conjugates, >60 bispecific antibodies, >35 Fc-fusion proteins and >10 immuno-cytokines. Despite these innovations, technological advances are needed to address unmet medical needs with new pharmacological mechanisms. Age-related eye diseases are among the most common causes of blindness and poor vision in the world. Many such diseases affect the back of the eye, where the inaccessibility of the site of action necessitates therapeutic delivery via intravitreal (IVT) injection. Treatments administered via this route typically have vitreal half-lives <10 days in humans, requiring frequent administration. Since IVT injection is burdensome to patients, there exists a strong need to develop therapeutics with prolonged residence time in the eye. We report here a strategy to increase retention of a therapeutic fragment antibody (Fab) in the eye, using an anti-complement factor D Fab previously optimized for ocular delivery. Polyethylene glycol structures, varying in length, geometry and degree of branching, were coupled to the Fab via maleimide-activated termini. A screening strategy was developed to allow for key determinants of ocular half-life to be measured in vitro. After compound selection, a scalable process was established to enable tolerability and pharmacokinetic studies in cynomolgus monkeys, demonstrating an increase in vitreal half-life with no associated adverse events. Further, we show that the technique for compound selection, analytical characterization, and scalable production is general for a range of antibody fragments. The application of the technology has broad impact in across many therapeutic areas with the first major advancement in the treatment of an important ocular disease.